Claus A. Andersson - 04 Nov 2021 Form 3 Insider Report for IO Biotech, Inc. (IOBT)

Footnote F1

Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series B Preferred Stock beneficially owned by the reporting person will automatically convert, for no additional consideration, into the number of shares of Common Stock reported in Column 3. These shares of Series B Preferred Stock have no expiration date.

Footnote F2

Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series C Preferred Stock beneficially owned by the reporting person will automatically convert, for no additional consideration, into the number of shares of Common Stock reported in Column 3. These shares of Series C Preferred Stock have no expiration date.

Footnote F3

Sunstone Life Science Ventures Fund III K/S ("Sunstone Fund III"). Sunstone LSV General Partner III ApS ("Sunstone LSV GP III") is the general partner of Sunstone Fund III and has voting and dispositive power over all of the shares of held by Sunstone Fund III. The reporting person is a General Partner of Sunstone Life Science Ventures A/S and a member of the executive board of Sunstone LSV GP III, and shares voting and dispositive power with respect to the shares held by Sunstone Fund III. The reporting person disclaims beneficial ownership of the shares held directly by Sunstone Fund III except to the extent of his pecuniary interest therein.